EMA Panel Recommends Baxfendy for Hard-to-Control Hypertension

Baxfendy is poised to become the European Union’s first approved aldosterone synthase inhibitor after winning a key recommendation from the European Medicines Agency to treat hard-to-control arterial hypertension.

  • What it is: Baxfendy (baxdrostat) blocks a specific enzyme that tells the kidneys to hold onto salt and water, which drives up blood pressure.
  • Who it is for: Adults whose high blood pressure remains uncontrolled despite taking at least two existing blood pressure medications.
  • What to watch: The most frequent side effect observed in clinical testing was elevated blood potassium, known as hyperkalemia.

European regulators have advanced AstraZeneca AB’s novel cardiovascular medication toward formal commercial clearance. At its November 2026 meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended granting marketing authorization for Baxfendy, according to Medscape.

The drug is designed for adult patients with arterial hypertension that fails to respond adequately to at least two standard antihypertensive medications. Insights.citeline.com reported that this regulatory milestone puts the treatment on course to become the European Union’s first approved aldosterone synthase inhibitor.

Baxdrostat works as a selective inhibitor of human aldosterone synthase, an enzyme responsible for producing aldosterone. This hormone contributes to elevated blood pressure by promoting sodium and water retention in the kidneys while simultaneously driving vascular dysfunction, inflammation, and fibrosis directly within blood vessels.

Baxfendy is designed to lower blood pressure by inhibiting the production of aldosterone
Photo: insights.citeline.com

The European Medicines Agency’s recommendation relies heavily on data from the phase 3 BaxHTN trial, which evaluated adults with seated systolic blood pressure ranging from 140 mm Hg to under 170 mm Hg, as detailed by Medscape. Investigators enrolled patients receiving stable multi-drug regimens, dividing them into cohorts receiving once-daily doses of baxdrostat 1 mg, baxdrostat 2 mg, or a placebo alongside background therapy.

At the 12-week mark, the least-squares mean change in seated systolic blood pressure dropped by 14.5 mm Hg with the 1-mg dose and by 15.7 mm Hg with the 2-mg dose, compared to a reduction of just 5.8 mm Hg in the placebo group. These figures correspond to placebo-corrected reductions of 8.7 mm Hg for the 1-mg dose and 9.8 mm Hg for the 2-mg dose.

Treatment Group Systolic Blood Pressure Change Placebo-Corrected Reduction
Baxdrostat 1 mg -14.5 mm Hg -8.7 mm Hg
Baxdrostat 2 mg -15.7 mm Hg -9.8 mm Hg
Placebo -5.8 mm Hg Reference

While European regulators advance the medication toward authorization, market dynamics differ across the Atlantic. Insights.citeline.com said that US payers and prescribers are weighing up the new drug class.

Following final marketing authorization by the European Commission, detailed prescribing information and official recommendations will be published in all official European Union languages via the Summary of Product Characteristics on the European Medicines Agency website.

Patients considering new therapeutic options for resistant hypertension must carefully evaluate biochemical risks with their treating clinician. Clinical trials for baxdrostat identified hyperkalemia—elevated blood potassium levels—as the most common side effect.

Potassium levels exceeding 6.0 mmol/L occurred in 2.3% of patients taking the 1-mg dose, 3.0% of those on the 2-mg dose, and 0.4% in the placebo arm. Patients should discuss potassium monitoring and their individual risk factors with their treating clinician.

  • European Medicines Agency (EMA): Committee for Medicinal Products for Human Use (CHMP) November 2026 Meeting Reports
  • Insights Citeline: Product Reviews and Market Access Analysis for Baxfendy

Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

Photo of author

Priya Deshmukh - Senior Editor, Health

Priya Deshmukh Senior Editor, Health Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.

WhatsApp’s New “Zaps” Feature: Ephemeral Photos and Videos That Disappear After Viewing

James Trafford: How ex-Man City Goalkeeper Is Challenging Jordan Pickford as England’s No 1 After Heroics vs Spain